RGEN
Repligen Corp
Price:  
113.11 
USD
Volume:  
863,376.00
United States | Life Sciences Tools & Services
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

RGEN EV/EBITDA

-54.5%
Upside

As of 2026-04-30, the EV/EBITDA ratio of Repligen Corp (RGEN) is 45.12. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RGEN's latest enterprise value is 6,355.60 mil USD. RGEN's TTM EBITDA according to its financial statements is 140.86 mil USD. Dividing these 2 quantities gives us the above RGEN EV/EBITDA ratio.

Range Selected
Trailing P/E multiples 13.1x - 21.4x 17.4x
Forward P/E multiples 23.2x - 27.2x 26.0x
Fair Price 33.04 - 61.88 51.51
Upside -70.8% - -45.3% -54.5%
113.11 USD
Stock Price
51.51 USD
Fair Price

RGEN EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2026-04-28 46.85
2026-04-27 47.19
2026-04-24 46.92
2026-04-23 45.50
2026-04-22 49.64
2026-04-21 52.96
2026-04-20 52.68
2026-04-17 52.37
2026-04-16 50.72
2026-04-15 52.65
2026-04-14 52.29
2026-04-13 48.92
2026-04-10 47.92
2026-04-09 47.79
2026-04-08 47.79
2026-04-07 45.99
2026-04-06 46.66
2026-04-02 46.99
2026-04-01 47.21
2026-03-31 47.01
2026-03-30 44.47
2026-03-27 43.92
2026-03-26 45.64
2026-03-25 45.60
2026-03-24 46.40
2026-03-23 46.42
2026-03-20 45.43
2026-03-19 46.92
2026-03-18 46.91
2026-03-17 47.59
2026-03-16 45.92
2026-03-13 45.56
2026-03-12 45.38
2026-03-11 47.57
2026-03-10 48.59
2026-03-09 51.04
2026-03-06 47.87
2026-03-05 49.89
2026-03-04 50.22
2026-03-03 49.10
2026-03-02 49.87
2026-02-27 51.37
2026-02-26 53.34
2026-02-25 52.74
2026-02-24 53.75
2026-02-23 54.04
2026-02-20 54.16
2026-02-19 54.77
2026-02-18 55.13
2026-02-17 54.05